Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey-Reference-Cited by-同舟云学术

Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey

Published:2022-02-07 Issue:6 Volume:70 Page:1685-1694
ISSN:0002-8614
Container-title:Journal of the American Geriatrics Society
language:en
Short-container-title:J American Geriatrics Society

Author:

DiStefano Michael J.¹²^ORCID,Alexander G. Caleb³⁴⁵,Polsky Daniel¹⁶⁷,Anderson Gerard F.¹⁵

Affiliation:

1. Department of Health Policy & Management Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA

2. Berman Institute of Bioethics Johns Hopkins University Baltimore Maryland USA

3. Center for Drug Safety and Effectiveness Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA

4. Department of Epidemiology Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA

5. Division of General Internal Medicine Johns Hopkins Medicine Baltimore Maryland USA

6. Carey Business School Johns Hopkins University Baltimore Maryland USA

7. Hopkins Business of Health Initiative Johns Hopkins University Baltimore Maryland USA

Funder

Arnold Ventures

Publisher

Wiley

Subject

Geriatrics and Gerontology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgs.17692

Reference19 articles.

1. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

2. The amyloid hypothesis on trial

3. Revisiting FDA Approval of Aducanumab

4. FeuersteinA HerperM GardeD.Inside ‘Project Onyx’: How Biogen used an FDA back channel to win approval of its polarizing Alzheimer's drug. Stathttps://www.statnews.com/2021/06/29/biogen-fda-alzheimers-drug-approval-aduhelm-project-onyx/. Published 2021. Accessed October 5 2021.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lessons Learned from Approval of Aducanumab for Alzheimer's Disease;Annual Review of Medicine;2024-01-29

2. Familiarity and Perceptions of Aducanumab in Caregivers of Hawaii Alzheimer’s Disease Patients: Results of a Telephone Survey;Cureus;2023-12-05

3. Efficacy of anti-amyloid-ß monoclonal antibody therapy in early Alzheimer’s disease: a systematic review and meta-analysis;Neurological Sciences;2023-11-17

4. Informing consent to antibodies in Alzheimer’s disease;BMJ;2023-10-11

5. The performance of plasma phosphorylated tau231 in detecting Alzheimer's disease: A systematic review with meta‐analysis;European Journal of Neuroscience;2023-07-27